603, 2025
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA January 9 - Osimertinib - NSCLC EGFR. The European [...]
1001, 2025
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA December 30 - Lazertinib + amivantamab – NSCLC EGFR. [...]
1311, 2024
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA August 22 – Amivantamab – NSCLC EGFR. The European Commission (EC) [...]
1107, 2024
Shooting Cancer Highlights – Periodic Focus on regulatory status of new targeted therapies in oncology
Shooting Cancer Highlights – Periodic Focus on regulatory status [...]
1303, 2024
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA November 15 - Dabrafenib – LGG/HGG BRAF. The [...]
2112, 2023
Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – November 2023
EMA October 18 – Trastuzumab deruxtecan – NSCLC HER2. The European Commission (EC) [...]
611, 2023
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – September and October 2023
EMA September 6 - Pembrolizumab – GC/GEJC HER2/PD-L1. The [...]
611, 2023
Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – September and October 2023
EMA September 6 - Pembrolizumab – GC/GEJC HER2/PD-L1. The [...]